CTLA4 and metastatic melanoma: Starting with the approval of anti-cytotoxic T lymphocyte-associated protein 4 (anti-CTLA-4) for advanced metastatic malignant melanoma in 2011, immune checkpoint inhibitors (ICIs) have since included antibodies against programmed cell death 1 (PD-1) as well.